Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.75 Analyst target: $5.00 Upside: 565.87%
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
See the full interactive analysis & chart →Informational only — not investment advice.